DrugPatentWatch Database Preview
Drugs in Development Information for Danoprevir
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Danoprevir?
Danoprevir is an investigational drug.
There have been 31 clinical trials for Danoprevir.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis. The leading clinical trial sponsors are Hoffmann-La Roche, Ascletis Pharmaceuticals Co., Ltd., and [disabled in preview].
There are twenty-eight US patents protecting this investigational drug and four hundred and eighty-nine international patents.
Summary for Danoprevir
| US Patents | 28 |
| International Patents | 489 |
| US Patent Applications | 48 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2016-06-01) |
| Vendors | 40 |
Recent Clinical Trials for Danoprevir
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetics and Safety of Ravidasvir in Combination With Danoprevir/r in Healthy Volunteers China | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 |
| Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r in Treatment-naive, Non-cirrhotic, Genotype1 CHC Patients. | Ascletis Pharmaceuticals Co., Ltd. | Phase 2/Phase 3 |
| Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 |
Clinical Trial Summary for Danoprevir
Top disease conditions for Danoprevir
Top clinical trial sponsors for Danoprevir
US Patents for Danoprevir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Danoprevir | Start Trial | Method for treating HCV | AbbVie Inc. (North Chicago, IL) | Start Trial |
| Danoprevir | Start Trial | Macrocyclic compounds as inhibitors of viral replication | Intermune, Inc. (Brisbane, CA) | Start Trial |
| Danoprevir | Start Trial | Macrocyclic inhibitors of hepatitis C virus replication | InterMune, Inc. (Brisbane, CA) | Start Trial |
| Danoprevir | Start Trial | Process for the preparation of a macrocycle | Roche Palo Alto LLC (South San Francisco, CA) | Start Trial |
| Danoprevir | Start Trial | Ruthenium complexes as catalysts for metathesis reactions | Roche Palo Alto LLC (South San Francisco, CA) | Start Trial |
| Danoprevir | Start Trial | Macrocyclic inhibitors of hepatitis C virus replication | InterMune, Inc. (Brisbane, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Danoprevir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Danoprevir | Australia | 2014239563 | 2033-03-14 | Start Trial |
| Danoprevir | Australia | 2015240754 | 2033-03-14 | Start Trial |
| Danoprevir | Australia | 2016202823 | 2033-03-14 | Start Trial |
| Danoprevir | Australia | 2016291154 | 2033-03-14 | Start Trial |
| Danoprevir | Australia | 2017248487 | 2033-03-14 | Start Trial |
| Danoprevir | Australia | 2018201011 | 2033-03-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
